Archive: June 2024
Feature Article
Antibody-Drug Conjugates in Advanced Lung Cancer: Is This a New Frontier?
Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]
Feature Article
Redefining the Standard of Care for Low-Grade Serous Ovarian Cancer
Abstract: Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted […]
Melanoma in Focus
The Evolving Role of Surgery in Melanoma
H&O What has been the traditional role of surgery in melanoma? VKS Surgery has long been the mainstay of treatment for all early-stage melanomas. We used […]
CLL
Pirtobrutinib in Relapsed or Refractory CLL and SLL
H&O What are the mechanisms of action of pirtobrutinib and other Bruton tyrosine kinase (BTK) inhibitors? JW All of the currently available BTK inhibitors work by […]
Advances in Drug Development
New Drug Approvals for Prostate Cancer
H&O What are the most recent drug approvals for prostate cancer? IT The most recent drug approvals for men with prostate cancer primarily consist of “me-too” […]
Prostate Cancer
STEAP1 as a Potential Target for New Therapies in Prostate Cancer
H&O What is six-transmembrane epithelial antigen of prostate 1 (STEAP1)? WKK STEAP1 was first described more than 2 decades ago. It is a cell-surface antigen that […]